SCHEMBL3035374

SCHEMBL3035374

CC(C)n1c(=O)oc2cc([N+](=O)[O-])cc(F)c21

nearest known ligand 0.35

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 4/20 0.35
ALDH1A1 P00352 4/20 0.35
MEN1 O00255 3/20 0.35
IDO1 P14902 2/20 0.34
MAPT P10636 3/20 0.33
PGR P06401 1/20 0.33
TDP1 Q9NUW8 2/20 0.33
LMNA P02545 1/20 0.33
TSHR P16473 1/20 0.32
HIF1A Q16665 1/20 0.31
KDM4E B2RXH2 1/20 0.30
MAOA P21397 1/20 0.30
MAOB P27338 1/20 0.30
CA12 O43570 1/20 0.30
CA9 Q16790 1/20 0.30
CYP19A1 P11511 1/20 0.30
THRB P10828 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3032925 0.81 IDO1 (0.36) KMT2AALDH1A1MEN1IDO1MAPT
SCHEMBL3038133 0.81 IDO1 (0.41) KMT2AALDH1A1MEN1IDO1MAPT
SCHEMBL2600314 0.74 MEN1 (0.52) KMT2AALDH1A1MEN1IDO1MAPT
SCHEMBL30349819 0.71 IDO1 (0.52) KMT2AALDH1A1MEN1IDO1MAPT
SCHEMBL6753276 0.66 KMT2A (0.38) KMT2AALDH1A1MEN1MAPTPGR
SCHEMBL23926471 0.66 IDO1 (0.43) KMT2AALDH1A1MEN1IDO1MAPT
SCHEMBL31717090 0.66 TDP1 (0.46) KMT2AALDH1A1MEN1MAPTTDP1
SCHEMBL2542510 0.65 IDO1 (0.40) KMT2AALDH1A1MEN1IDO1MAPT
SCHEMBL26630320 0.64 KMT2A (0.35) KMT2AALDH1A1MEN1MAPTLMNA
SCHEMBL26925116 0.64 MEN1 (0.60) KMT2AMEN1MAPTPGRTDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7645781-B2 N-aryl-2-oxazolidinone-5-carboxamides and their derivatives PFIZER INC (US) 2010-01-12 US disclosed
US-20070015801-A1 N-aryl-2-oxazolidinone-5-carboxamides and their derivatives THOMAS RICHARD C 2007-01-18 US disclosed
US-7141588-B2 N-aryl-2-oxazolidinone-5-carboxamides and their derivatives PFIZER, INC. (US) 2006-11-28 US disclosed
EP-1478629-B1 N-ARYL-2-OXAZOLIDINONE-5-CARBOXAMIDES AND THEIR DERIVATIVES AND THEIR USE AS ANTIBACTERIALS PHARMACIA & UPJOHN CO LLC (US) 2006-10-11 EP disclosed
US-6919329-B2 N-Aryl-2-oxazolidinone-5-carboxamides and their derivatives PHARMACIA & UPJOHN COMPANY (US) 2005-07-19 US disclosed
EP-1478629-A1 N-ARYL-2-OXAZOLIDINONE-5-CARBOXAMIDES AND THEIR DERIVATIVES AND THEIR USE AS ANTIBACTERIALS PHARMACIA & UPJOHN COMPANY (US) 2004-11-24 EP disclosed
US-20040147760-A1 N-aryl-2-oxazolidinone-5-carboxamides and their derivatives PHARMACIA & UPJOHN COMPANY 2004-07-29 US disclosed
US-20040044052-A1 N-Aryl-2-oxazolidinone-5-carboxamides and their derivatives PHARMACIA & UPJOHN COMPANY 2004-03-04 US disclosed
WO-2003072553-A1 N-ARYL-2-OXAZOLIDINONE-5-CARBOXAMIDES AND THEIR DERIVATES AND THEIR USE AS ANTIBACTERIALS PHARMACIA & UPJOHN COMPANY (US) 2003-09-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040147760-A1 N-aryl-2-oxazolidinone-5-carboxamides and their derivatives OXA1L, AADAC, MT-ND5 KMT2A 1273/4885ALDH1A1 956/4885MEN1 3522/4885
US-20040044052-A1 N-Aryl-2-oxazolidinone-5-carboxamides and their derivatives OXA1L, AADAC, MT-ND5 KMT2A 1273/4885ALDH1A1 956/4885MEN1 3522/4885
US-20070015801-A1 N-aryl-2-oxazolidinone-5-carboxamides and their derivatives OXA1L, AADAC, MT-ND5 KMT2A 1273/4885ALDH1A1 956/4885MEN1 3522/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.